The FDA Approved a New Drug To Treat Alzheimer’s, but Medicare Won’t Always Pay for It – A Doctor Explains Biogen’s Aduhelm

On April 8, 2022, Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease treatment. The decision means that only patients...

The post The FDA Approved a New Drug To Treat Alzheimer’s, but Medicare Won’t Always Pay for It – A Doctor Explains Biogen’s Aduhelm appeared first on SciTechDaily.

from SciTechDaily https://ift.tt/7qgOezi